MTMatthew Turnure

Matthew Turnure

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Matthew Turnure has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Drug overdose mortality among healthcare system patients and publicly and privately insured people in North Carolina, USA: 2014–2022

    by Raana Zakeri, Brian W Pence, Vanessa E Miller, Hillary Mortensen, Grace Yeboah-Kodie, Bethany DiPrete, Naoko Fulcher, Pasangi S Perera, Matthew M Turnure, Shabbar I Ranapurwala

    Background The drug overdose epidemic—responsible for approximately 108 000 deaths in the USA in 2022 and imposing a substantial economic burden—underscores the need to better understand population-specific risks. We compared overdose mortality rates in North Carolina across three cohorts—healthcare system patients, privately insured individuals and Medicaid enrollees—from 2014 to 2022. Methods Data from large integrated datasets for populations of interest were linked with death certificate records for 2014–2022. Overdose deaths involving all-drug, opioids or polydrugs were identified using International Classification of Disease Version 10 codes for primary and contributing cause of death among individuals aged 12–64. Using North Carolina population as the reference, age-, sex- and calendar year-adjusted overdose mortality rates and standardised mortality ratios were respectively calculated through direct and indirect standardisation. Results In North Carolina general population, overdose mortality rates per 100 000 person-years for all-drug, opioids and polydrugs were 28.8, 25.0 and 18.0 respectively. Among healthcare system patients, the corresponding adjusted rates were substantially higher—105.2, 86.4 and 62.8 (standardised mortality ratios: 3.4, 3.2, 3.3). Medicaid enrollees also had elevated rates—85.4, 63.6 and 46.4 (standardised mortality ratios: 2.8, 2.4, 2.4). In contrast, privately insured individuals had lower rates—16.1, 12.3 and 8.6 (standardised mortality ratios: 0.5, 0.5, 0.5). Conclusions Individuals receiving care within the health system experienced the highest overdose mortality rates, followed by those with Medicaid coverage, with both exceeding rates observed among privately insured individuals. These findings highlight significant socioeconomic health inequalities that could benefit from targeted overdose prevention interventions among resource-limited populations.

  • Open Access

    Treatment Patterns in Metastatic Bladder Cancer in Japan: Results of the CancerMPact ® Survey 2020

    by Ana Paula A Bueno, Otavio Clark, Matthew Turnure, Eloisa S Moreira, Akira Yuasa, Shigeru Sugiyama, Melissa Kirker, Si Li, Ningqi Hou, Jane Chang, et al.

    Aim: To assess physician-reported treatment of metastatic bladder cancer in Japan. Methods: 76 physicians completed the CancerMPact® survey in July 2020, considering patients treated within 6 month... Plain language summary In 2020, researchers surveyed 76 Japanese doctors who specialized in bladder and urinary system disorders about how they treated people with bladder cancer. Cisplatin, a type... Tweetable abstract CancerMPact® Survey 2020: Physician-reported treatment patterns in #MetastaticUrothelialCarcinoma in Japan.


  • Open Access

    Physician Reported Treatment Patterns and Outcomes in Metastatic Bladder Cancer in the USA: The CancerMPact ® Survey 2020

    by Ana Paula A Bueno, Otavio Clark, Matthew Turnure, Eloisa S Moreira, Jane Chang, Ningqi Hou, Si Li, Ruth Kim, Mairead Kearney, Melissa Kirker, et al.

    Aim: This study assessed physician-reported treatment patterns for metastatic bladder cancer. Materials & methods: A total of 106 US-based physicians were surveyed in 2020 using the CancerMPact® on... Plain language summary In 2020, researchers surveyed 106 US doctors about how they treated people with advanced bladder cancer. Cisplatin, a chemotherapy drug, was the most common first treatment t... Tweetable abstract We present physician-reported treatment patterns in #MetastaticUrothelialCarcinoma in the US from the 2020 CancerMPact® survey. Cisplatin and an immune checkpoint inhibitor or ca...


  • Open Access

    Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPact® Survey 2018

    by Eloisa de Sã¡ Moreira, David Robinson, Stephanie Hawthorne, Linda Zhao, Madelyn Hanson, Gena Kanas, Matthew Turnure, Christine Davis, Otavio Clark

    Purpose: We describe patterns of care and treatment outcomes for non-metastatic PCa (nmPCA), either hormone-sensitive or castration-resistant, in the United States of America (USA) in 2018. Methods: A survey (CancerMPact®) recruited physicians nationwide to answer an online questionnaire about how they treated patients with nmPCA. Questions covered aspects of treatment at all disease stages. Board-certified urologists and oncologists with at least five years of clinical practice and who treated at least 30 PCa patients monthly were included. Results: The survey included responses from ninety-four physicians with an average of 17.5 years of clinical practice, who had treated a combined average of 4415 patients with nmPCA per month in 2018. Approximately 40% of patients in stage I were managed with either active surveillance or observation/no therapy, decreasing to 20%, 8% and 6% in stages II, III and IV(M0), respectively. Intensity-modulated radiotherapy was favored over other radiotherapy modalities, with rates of use ranging between 60% and 69% depending on disease stage. Leuprolide as monotherapy or in combination with enzalutamide, abiraterone or bicalutamide were the most common systemic treatment options for non-metastatic hormone-sensitive PCa (nmHSPC) patients with the first or second recurrence. Only 16.5% of non-metastatic castration-resistant PCa (nmCRPC) patients did not relapse within five years of initial therapy for nmCRPC. Conclusion: While PCa treatment recommendations are rapidly changing due to advances in treatment, we observed great concordance between their most current versions and real-world data treatment patterns reported by US physicians.


  • Open Access

    Treatment of Advanced/Metastatic Melanoma in the United States and Western Europe: Results of the CancerMPact Survey

    by Stephanie Hawthorne, Linda Zhao, Madelyn Hanson, Gena Kanas, Christine Davis, David Robinson, Matthew Turnure, Otavio Clark

    Context: Melanoma treatment has substantially changed over the last several years, yet little information regarding physician’s preferences around treatment exists. Objective: Our aim is to describe the results of the CancerMPact (CMP) survey performed in 2019 about the treatment of advanced/metastatic melanoma. Methods: CMP is a data source from Kantar, Health Division, containing data on cancer epidemiology and treatment. Once a year, Kantar performs a series of surveys with specialists in the field of interest in the United States of America (USA), Western Europe (WE), Japan, and China. The results of the survey reported in this work comprise the answers from 94 USA and 99 WE physicians about the treatment of melanoma. Results: In the first-line for the BRAF wild-type population, immuno-oncology (IO) drugs including nivolumab, ipilimumab or pembrolizumab (alone or in combination) were used in 80.1% of the cases in the USA and 70.6% in WE. Conventional chemotherapy or cytokine-based treatments were used in 16.4% of the USA patients and 28.2% in WE. In the second-line in the USA, 45.8% of BRAF wild-type patients received IO drugs, while 45.0% of patients received conventional chemotherapy or cytokine-based treatments. The majority of patients with BRAF mutant advanced/metastatic melanoma were treated in the first-line with BRAF-targeted therapy (61.3% USA, 71.9% WE), and few patients received conventional chemotherapy or cytokine-based treatments (11.9% USA, 12.4% WE); the most commonly used BRAF-targeted therapy was the combination of dabrafenib plus trametinib. In the second-line, BRAF mutant patients received IO drugs (45.1% USA, 53.7% WE), targeted therapy (37.6% USA, 32% WE) or conventional chemotherapy/cytokine-based treatments (14.4% USA, 11.7% WE). Conclusion: The use of IO or targeted therapy for patients with advanced/metastatic melanoma is the preferred treatment strategy by physicians in the USA and WE based on BRAF mutation status. Many patients still receive conventional chemotherapies or cytokines with unsubstantial benefit, especially in recurrent patients of BRAF wild type.